YOSHINDO INC.
Biocon Biologics inks out-licensing agreement with Yoshindo IncUnder the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- develo...
Lupin to set up two new R&D centres in USLupin had also increased research and development spending to Rs 958.28 crore in FY'14 as compared to Rs 770.85 crore in the FY'13.
Lupin forms Joint Venture with Japan's Yoshindo IncLupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...
- Load More